Cancer treatment-related cardiotoxicity: A focus on sacubitril/valsartan
Feng Hu 1,2,3 #, Huajiong Yu 4 #,
Weiping Du 1,2, Mengjia Chen 5, Jia
Su 1,2 *, Xiaomin Chen 1,2 *
1 Department of Cardiovascular Medicine, Ningbo First
Hospital, Ningbo, 315010, Zhejiang, China.
2 Key Laboratory of Precision Medicine for
Atherosclerotic Diseases of Zhejiang Province, Ningbo, 315010, Zhejiang,
China.
3 Department of Cardiovascular Medicine, the Second
Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi,
PR China
4 Department of Cardiology, Shulan (Hangzhou) Hospital
Affiliated to Zhejiang Shuren University, Shulan International Medical
College, Hangzhou, 310003, Zhejiang, PR China
5 Department of Cardiology, the First Affiliated
Hospital College of Medicine, Zhejiang University, Hangzhou, 310003,
Zhejiang University, China
# FH and HJY contributed to this study equally.
*Correspondence:
Jia Su, MD, PhD.
Department of Cardiovascular Medicine, Ningbo First Hospital, liuting
street No.59, Ningbo, 315010, Zhejiang, China.
Email: nbsj54@126.com
Xiaomin Chen, MD, PhD.
Department of Cardiovascular Medicine, Ningbo First Hospital, liuting
street No.59, Ningbo, 315010, Zhejiang, China.
E-mail: chxmin@hotmail.com